PR1 peptide vaccine + sargramostim

PR1 is a peptide-based cancer vaccine consisting of a 9-amino acid HLA-A2-restricted peptide (sequence: VLQELNVTV) derived from the leukemia-associated antigens proteinase 3 (PR3) and neutrophil elastase (NE). These proteins are primary granule proteins that are overexpressed in the blasts of patients with acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The vaccine is designed to stimulate a specific cytotoxic T-lymphocyte (CTL) response to target and eliminate residual leukemic cells. It is typically co-administered with sargramostim (GM-CSF), which serves as an immunological adjuvant to promote the recruitment and maturation of antigen-presenting cells at the injection site. Developed by The Vaccine Company, the PR1 vaccine reached Phase 3 clinical evaluation for maintaining remission in AML patients, although the pivotal trial was ultimately terminated.

Other names

PR1 leukemia peptide vaccinePR-1 leukemia peptide vaccinePR 1 leukemia peptide vaccineR-The Vaccine Company-leukemia (acute myeloid)